Last year, 100 leading oncologists from around the world wrote an open letter in the journal Blood calling for ___36___ the
price of cancer drugs. Dr Brian Druker, director of the Knight Cancer Institute and one of the signatories, has asked: "If you are
making $3bn a year on a cancer drug like Gleevec, could you ___37___ $2bn? When do you cross the line from essential
profits to profiteering?” And it's not just cancer drugs. Between April and June this year, drug company Gilead clocked sales of
$3.5bn for its latest hepatitis C drug Sovaldi. Drug companies justify the high prices they charge ___38___ their research and
development costs are huge. On average, only three in 10 drugs launched are profitable, with one of those going on to be a
blockbuster with $1bn-plus revenues a year. Many more do not even make it to market. However, drug companies ___39___
more on marketing drugs than on developing them. And besides, profit margins ___40___ account R&D costs. 【題組】38. (A) to argue about (B) to argue with (C) by arguing that (D) by arguing for
寫作批改
VIP與詳解卡管理
私人筆記( 0 )